Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson’s disease, as an anti-cancer stem cell drug

CEP-1347 is a mixed lineage kinase inhibitor tested in a large-scale phase 2/3 clinical trial in early Parkinson’s disease, in which its safety and tolerability, but nevertheless not efficacy, was demonstrated. Here we identify by drug repositioning CEP-1347 as a potential anti-cancer stem cell drug...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Okada, Masashi, Takeda, Hiroyuki, Sakaki, Hirotsugu, Kuramoto, Kenta, Suzuki, Shuhei, Sanomachi, Tomomi, Togashi, Keita, Seino, Shizuka, Kitanaka, Chifumi
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5706919/
https://ncbi.nlm.nih.gov/pubmed/29212273
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22033
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items